October 13, 2023 – Page 3

REPEAT – Biomerica Reports First Quarter 2024 Financial Results

Written by Customer Service on October 13, 2023. Posted in Earnings Releases And Operating Results.

Revenues excluding Covid test sales increased 16.3% for first fiscal quarter of 2024 vs the first fiscal quarter of 2023 Company believes current cash position, forecasted revenue growth and corporate strategy is expected to enable it to achieve profitability GAAP gross margin percentage of 24.1% for the first fiscal quarter of 2024 improved substantially over -3.4% for the first fiscal quarter of 2023 Company completes pre-launch phase for inFoods IBS; veteran Vice President of sales and national accounts hired along with regional key account representatives IRVINE, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) — Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the first quarter of fiscal 2024 ended August 31, 2023. Recent...

Senior Management Appointments and Conditional RSU Awards

Written by Customer Service on October 13, 2023. Posted in Public Companies.

TORONTO, ONTARIO, Oct. 13, 2023 (GLOBE NEWSWIRE) — (“Amaroq,” “Company” or the “Corporation”) Senior Management Appointments and Conditional RSU Awards TORONTO, ONTARIO – October 13, 2023 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ), an independent mine development corporation with a substantial land package of gold and strategic mineral assets across in Southern Greenland, is pleased to provide an update on senior management appointments. Appointment of Executive Vice President Joan Plant has been appointed Executive Vice President. Joan has 13 years of experience operating in Greenland, and has worked on the Nalunaq project since 2010. During this time, she has built a strong relationship with the Government of Greenland whilst successfully applying her in-depth knowledge and expertise covering all aspects of the...

Revenue growth as of September 2023 by 40%

Written by Customer Service on October 13, 2023. Posted in Earnings Releases And Operating Results.

Press release Ecully, October 13, 2023 – 6 p.m. 9-month revenue up 40% at €7.5 million In thousands of euros Unaudited data 2023 2022 % change Q1 revenue 2,399 1,342 +79% Q2 revenue 3,034 1,770 +71% Q3 revenue 2,077 2,249 -8% 9M revenue* 7,509 5,361 +40% * 9M 2022 revenue included the share of revenue derived from Spine Innovations following its consolidation on July 21, 2022, i.e. €0.9 million. Spineway recorded revenue of €2.1 million in the third quarter of 2023, taking the 9-month total to €7.5 million, a 40% increase compared with 2022. Revenue growth over the first 9 months was driven mainly by sales by Spine Innovations, consolidated in July 2022. As announced, third-quarter revenue was automatically impacted by a less favorable impact from change in scope. Sales in Asia amounted to €1.2 million over 9 months...

Versus Systems Inc. Announces Pricing of $3.0 Million Public Offering

Written by Customer Service on October 13, 2023. Posted in Public Companies.

LOS ANGELES, Oct. 13, 2023 (GLOBE NEWSWIRE) — Versus Systems Inc. (“Versus” or the “Company”) (NASDAQ: VS), today announced the pricing of its reasonable best efforts public offering of 13,043,490 of its common shares (or common share equivalents in lieu thereof) and accompanying warrants to purchase up to an aggregate of 13,043,490 common shares at a combined public offering price of $0.23 per share and accompanying warrant, resulting in gross proceeds of approximately $3.0 million. The warrants have an exercise price of $0.23 per share, are immediately exercisable upon issuance and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about October 17, 2023, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the...

Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting

Written by Customer Service on October 13, 2023. Posted in Public Companies.

Clinical dose escalation data for RMC-6236, a RASMULTI(ON) Inhibitor, show oral bioavailability, well-tolerated safety profile and preliminary evidence of anti-tumor activity across multiple RAS mutations First clinical data presentation for RMC-6291, a RASG12C(ON) Inhibitor, highlights encouraging initial tolerability, safety and differentiated anti-tumor activity Investor webcast to be held Sunday, October 22 at 12:30pm Eastern Time REDWOOD CITY, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced encouraging preliminary clinical data for RMC-6236, its RASMULTI(ON) Inhibitor, and RMC-6291, its RASG12C(ON) Inhibitor, from the respective Phase 1/1b studies. These data were presented during the...

ROBIT PLC: REPURCHASE OF OWN SHARES 13 OCTOBER 2023

Written by Customer Service on October 13, 2023. Posted in Public Companies.

ROBIT PLC STOCK EXCHANGE RELEASE 13 OCTOBER 2023 AT 18.45 EEST ROBIT PLC: REPURCHASE OF OWN SHARES 13 OCTOBER 2023 Robit Plc Nasdaq Helsinki Ltd Date 13.10.2023 Exchange transaction BUY Share trading code ROBIT Amount, shares 1693 Average price / share, EUR 1,429690 Total cost, EUR 2420,46 Robit Plc now holds a total of 51 873 shares including the shares repurchased on 13 October 2023. Detailed information concerning the repurchase is attached to this stock exchange release. On behalf of Robit Plc OP Corporate Bank Lasse Jaakonmäki Further information:Robit PlcArto Halonen, Group CEO+358 40 028 0717arto.halonen@robitgroup.com Distribution:Nasdaq Helsinki LtdKey mediawww.robitgroup.com Robit is the specialist focused on high quality drilling consumables for the mining and construction markets...

Oma Savings Bank Plc – Acquisition of own shares 13.10.2023

Written by Customer Service on October 13, 2023. Posted in Public Companies.

Oma Savings Bank Plc Stock Exchange Release 13.10.2023 Oma Savings Bank Plc: Acquisition of own shares 13.10.2023 In the NASDAQ OMX Helsinki Trade date 13.10.2023 Bourse trade Buy Share OMASP Amount 2,202 Shares Average price/ share 20.9291 EUR Total cost 46,085.88 EUR Company now holds a total of 128 488 shares including the shares repurchased on 13.10.2023 On behalf of Oma Savings Bank Plc Nordea Bank Finland Plc Janne Sarvikivi Sami Huttunen For further information, please contact: Sarianna Liiri CFO Tel. +358 40 835 6712 sarianna.liiri@omasp.fi Minna Sillanpää CCO Tel. +358 50 66592 minna.sillanpaa@omasp.fi www.omasp.fi...

Carlyle Secured Lending, Inc. Schedules Third Quarter 2023 Financial Results and Investor Conference Call

Written by Customer Service on October 13, 2023. Posted in Public Companies.

NEW YORK, Oct. 13, 2023 (GLOBE NEWSWIRE) — Carlyle Secured Lending, Inc. (“Carlyle Secured Lending”) (NASDAQ: CGBD) will host a conference call at 10:00 a.m. EDT on Wednesday, November 8, 2023 to announce its third quarter 2023 financial results. A news release containing the quarterly results will be issued after market close on Tuesday, November 7, 2023. The conference call will be available via public webcast via a link on Carlyle Secured Lending’s website at carlylesecuredlending.com and will also be available on the website soon after the call’s completion. About Carlyle Secured Lending, Inc. Carlyle Secured Lending, Inc. is a publicly traded (NASDAQ: CGBD) business development company (“BDC”) which began investing in 2013. Carlyle Secured Lending focuses on providing directly originated, financing solutions across the...

Banco Santander Chile: Announces Third Quarter 2023 Analyst and Investor Webcast / Conference Call

Written by Customer Service on October 13, 2023. Posted in Public Companies.

SANTIAGO, Chile, Oct. 13, 2023 (GLOBE NEWSWIRE) — You are cordially invited to participate in Banco Santander Chile’s (NYSE: BSAC) conference call-webcast on Friday, November 3, 2023, at 10.00 AM (New York Time) where we will discuss 3Q 2023 financial results. The Bank’s Officers participating in the conference call are: Emiliano Muratore, CFO, Cristian Vicuña, Chief Strategy Officer & Head of IR and Carmen Gloria Silva, Economist. A question and answer session will follow the presentation. The Management Commentary report will be published on October 31, 2023, before the market opens. The quiet period begins on October 17. To participate, the webcast presentation can be viewed at: https://mm.closir.com/slides?id=720987 Or please dial in using any of the below numbers: United Kingdom+44 203 984 9844 USA+1 718 866...

Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)

Written by Customer Service on October 13, 2023. Posted in Public Companies.

The opinion was based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and extensive nonclinical development program.2,3 If approved by the European Medicines Agency, rezafungin could be the first new treatment option in over 10 years for patients with invasive candidiasis.4 SAN DIEGO and CAMBRIDGE, England, Oct. 13, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, and Mundipharma today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for rezafungin...

Day: October 13, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice